RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Clinical trials for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase trial is testing the safety and best dose of two drugs, M1774 and ZEN-3694, given together to patients with recurrent ovarian or endometrial cancer. The drugs work by blocking enzymes that cancer cells need to grow. The study aims to find a dose that is safe and …
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cocktail aims to boost immune attack on ovarian cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to outsmart resistant ovarian cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two targeted drugs—abemaciclib and olaparib—can help women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 42 participants to find the safest dose and check for side effects.…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo targets tough ovarian cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called DT2216 combined with the chemotherapy paclitaxel in people whose ovarian cancer has returned and is resistant to platinum-based treatments. The main goal is to find the highest safe dose of DT2216 when given with paclitaxel. About 30…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Elizabeth Stover, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Supercharged immune cells take on tough ovarian cancers
Disease control Recruiting nowThis early-phase study tests a new treatment for people with ovarian cancer that has returned or is resistant to standard platinum chemotherapy. The treatment uses a patient's own immune cells (T cells), which are trained in a lab to recognize and attack a protein called MUC1 fou…
Matched conditions: RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC